Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Brazil
/
Healthcare
/
Hapvida Participações e Investimentos
HAPV3
Hapvida Participações e Investimentos
Rising Litigation And Inflation Will Undermine Brazil Healthcare
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
03 Jul 25
Updated
24 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
R$45.00
22.5% undervalued
intrinsic discount
24 Jul
R$34.88
Loading
1Y
-47.4%
7D
-3.6%
Author's Valuation
R$45.0
22.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
R$45.0
22.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-2b
37b
2014
2017
2020
2023
2025
2026
2028
Revenue R$36.9b
Earnings R$1.6b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
7.36%
Healthcare Services revenue growth rate
0.28%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
18.35%
Calculation
R$1.61b
Earnings '28
x
22.02x
PE Ratio '28
=
R$35.50b
Market Cap '28
R$35.50b
Market Cap '28
/
480.06m
No. shares '28
=
R$73.96
Share Price '28
R$73.96
Share Price '28
Discounted to 2025 @ 18.02% p.a.
=
R$44.99
Fair Value '25